MedWatch

BioNTech/Pfizer vaccine is less effective against Delta variant

New studies indicate that the BioNTech Pfizer vaccine does not handle the Delta variant as well as other variants of the virus.

Photo: LUCY NICHOLSON/REUTERS / X90050

The covid-19 vaccine from BioNTech/Pfizer is not nearly as effective when it comes to the new Delta variant as it is on previous versions of the virus.

This is according to preliminary studies done by the Israeli Ministry of Health, according to the Financial Times.

The studies show that BioNTech/Pfizer's vaccine is 64 percent effective in preventing fully vaccinated people from being infected with the Delta variant. This is lower than for other strains of the virus, where the vaccine is 94 percent effective.

The same studies also show that the vaccine is 93 percent effective in preventing serious illness and hospitalization.

AGC Biologics contacted minister over Danish vaccine collaboration before PM announcement 

Sanofi to establish mRNA vaccine center with 400 employees  

Pfizer gives Danish PM cold shoulder: rejects idea of starting vaccine production in Denmark 

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs